Talaris Therapeutics Announces Conference Call to Highlight Presentations at the American Transplant Congress (ATC) and Provide a Data Update from its Phase 3 FREEDOM-1 Study

Rhea-AI Summary

Talaris Therapeutics (TALS), a late-stage cell therapy company, announced plans to hold a conference call on June 8, 2022, at 8:00 a.m. ET. This call will provide updates on their presentations at the American Transplant Congress and data from the ongoing Phase 3 FREEDOM-1 study focused on living donor kidney transplant recipients. Investors can join via phone or webcast through Talaris’ website.

The company is dedicated to transforming care for solid organ transplants and severe immune disorders.

Positive

• Upcoming conference call to discuss significant data updates from the Phase 3 FREEDOM-1 study.
• Focus on living donor kidney transplant, indicating strong potential for market impact.

Negative

• None.

BOSTON and LOUISVILLE, Ky., June 01, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced it will host a conference call to discuss its presentations at the American Transplant Congress (ATC) and provide a data update from its ongoing Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.

The conference call will be held on June 8, 2022 at 8:00 a.m. ET. To access the conference call, the dial-in numbers are 1-855-605-1739 for domestic callers and 1-914-987-7955 for international callers. The conference ID number for the live call will be 9988627. A live webcast of the conference call will also be available under "News & Events" in the Investors section of the Company's website at www.talaristx.com.

About Talaris Therapeutics
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders. Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.

Media Contact
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
(617) 903-8783

Investor Contact
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
(339) 970-2843

 

FAQ

What is the purpose of Talaris Therapeutics' upcoming conference call on June 8, 2022?

The conference call will discuss presentations from the American Transplant Congress and provide a data update from the Phase 3 FREEDOM-1 study in living donor kidney transplant recipients.

What is the FREEDOM-1 study being conducted by Talaris Therapeutics?

The FREEDOM-1 study is a Phase 3 clinical trial focused on evaluating the effectiveness of Talaris' cell therapy in living donor kidney transplant recipients.

How can I access the conference call for Talaris Therapeutics on June 8, 2022?

You can access the conference call by dialing 1-855-605-1739 for domestic calls or 1-914-987-7955 for international calls, or by joining the live webcast on Talaris' website.

What date will the data update from Talaris Therapeutics' FREEDOM-1 study be announced?

The data update will be discussed during the conference call on June 8, 2022.

What market implications might arise from Talaris Therapeutics' ongoing studies?

Depending on the outcomes of the FREEDOM-1 study, successful results could enhance Talaris' market position in cell therapies for organ transplantation.